David Luci

David Luci is the Chairman at Digital Prime Technologies. David has also served as the President and Chief Executive Officer at Acurx Pharmaceuticals, Inc., a early stage biopharmaceutical company focused on developing drugs that target difficult to treat bacterial infections. David has also been a Board Member at Ameri Holdings, Inc. and Director at PLx Pharma Inc. In addition, they served as the President & CEO, Director at Dipexium Pharmaceuticals, an early stage biopharmaceutical company focused on developing a topical antibiotic candidate for the treatment of infected diabetic foot ulcers. Most recently, David was the Director at Access Pharmaceuticals, Inc. and President & Director at MacroChem Corporation. Prior to that, they were the Executive Vice President, CFO and General Counsel at Bioenvision, Inc. (Nasdaq: BIVN), a Biotechnology company. David began their career as a Corporate Attorney at Paul, Hastings, Janofsky & Walker LLP where they worked on Mergers & Acquisitions; Corporate Finance transactions, licensing and drafting and negotiating of a wide variety of contracts for public and private clients. David then moved on to Ernst & Young LLP where they worked as a Senior Auditor.

David Luci attended Albany Law School from 1991 to 1994, where they were the Managing Editor of the Journal of Science & Technology. David graduated cum laude from Bucknell University in 1988 with a BSBA in Accounting and Business. David is also a CPA and JD.